Abstract

Itch is one of the major complications of skin diseases. Although there are various substances that induce itch or pruritus, it is evident that histamine is the best known endogenous agent that evokes itch. Even though histamine-induced itch has been studied for some time, the underlying mechanism of itch is just beginning to emerge. Although various downstream signaling pathways of histamine receptors have been revealed, more studies are required to determine the cause of histamine-induced itch. It appears that itch and pain involve different neuronal pathways. Pain generally inhibits itch, which indicates an inter-communication between the two. Complex interactions between itch and pain may be expected based on reports on disease states and opioids. In this review, we discuss the molecular mechanism and the pharmacological aspects of histamine-induced itch. Especially, the underlying mechanism of TRPV1 (an anti-pruritus target) has been determined to some extent.

Introduction

Itch is a sensation felt on skin, which causes the desire to scratch. Although itch might constitute an alert system against certain stimuli like mosquito bites, it can become stressful and exhausting when excessive. Indeed, patients with severe pruritus often find it difficult to lead a normal life due to itch-associated psychological disturbances, such as, depression or sleep deprivation [1,2]. Atopic dermatitis patients suffer from severe itch, and this disease is inadequately addressed by currently available medications. Therefore, an understanding of the mechanism of itch is essential in order to treat severe symptoms.

Although numerous substances are known to cause pruritus, such as, substance P, cytokines, proteases and so forth (for a detailed review on pruritogenic agents, see [3,4]), histamine is best known to evoke experimental itch when applied to the skin [5-9]. Recent itch-related studies have focused on non-histaminergic itch symptoms, but it is also of considerable importance that we understand the manner in which histamine induces itch. In this regard, it is worth mentioning that antihistamines are among the most widely-used drugs in the United States [10]. Therefore, in this review, we will focus mainly on experimental findings concerning histamine-induced itch.

Histamine and itch

Histamine is released from mast cells when tissues are inflamed or stimulated by allergens [11,12], and once released, histamine induces itch is triggered by the excitation of a subset of unmyelinated C-fibers [13]. Histamine receptors are known to mediate histamine-induced responses, and are members of the G-protein-coupled receptors. Four subtypes of histamine receptors have been identified to date, and histamine receptor subtype 1 (H1R) has been studied most extensively in the context of hista-
mine-induced itch. In fact, H1R blockers (antihistamines) are widely used to manage and alleviate itch symptoms [14]. However, the itch-reducing efficacies of these classical H1R antihistamines are debatable because some believe that the effect is attributable to sedation rather than to H1R antagonism [15]. It appears that H1R antagonism does, at least to some extent, attenuate histamine-induced itch, because non-sedative second generation H1R antihistamines are beneficial for the management of itch symptoms [16]. However, in contrast to the proven relation between H1R and itch induction, the involvement of histamine receptor subtype II (H2R) is less convincing. It is generally believed that H2R is at best, only marginally involved in histamine-induced itch process [17,18]. For instance, dimaprit (a H2R agonist) failed to cause scratching, and cimetidine (a H2R antagonist) failed to suppress histamine-induced itch in BalbC mice [19]. On the other hand, it is intriguing that histamine receptor subtype III (H3R) antagonists aggravate itch symptoms, which appears to contradict the aforementioned histamine-induced itch pathway [20]. For example, the blockade of H3R by H3R-specific antagonists (thioperamide or AQ0145) was found to significantly increase the incidence of scratching behavior in mice [21]. Furthermore, intradermal injections of idofenopropit or clobenpropit (also H3R antagonists) caused significant increases in scratching behavior in both mast cell-deficient and wild-type mice [22]. Currently, it appears that the itch elicited by H3 antagonism is mediated by substance P, another itch-inducing agent [23]. However, it could also be mediated by mixed responses from H3R and histamine receptor subtype IV (H4R), since clobenpropit (a H3R antagonist) is also an agonist of H4R [24]. H4R agonists cause scratching responses in mice, and are attenuated by pretreating animals with a selective H4R antagonist, like JNJ7777120 [25]. It is also noteworthy that scratching behaviors are almost completely abolished when H1R/H4R antagonists or H1 antagonist are co-administered to H4R-knockout mice, which suggests that H1R and H4R are key components of the itch response [25].

Summarizing, it appears that activated H1R and H4R are involved in the induction of itch, whereas H3R acts in the reverse manner. On the other hand, it appears that H2R has a minor role at most.

**The histamine signaling pathway in sensory neurons**

H1R is coupled with Gaα4 proteins, and this interaction activates phospholipase C (PLC) [26]. In line with this, it has been reported that histamine elevates calcium levels in rat cultured sensory neurons, and that this elevation is blocked by U73122 (a PLC inhibitor) [27]. Moreover, it was recently found that PLCβ3 (and not the other PLC isotypes) specifically mediates histamine-induced calcium responses via H1R in cultured sensory neurons [28]. On the other hand, stimulation of phospholipase A2 (PLA2) by H1R was found to mediate histamine-induced sensory neuron excitation [29,30]. Furthermore, Shim and colleagues showed that histamine induces itch by activating PLA2, lipooxygenase, and the TRPV1 signaling pathway [30]. Histamine induces inward currents that are blocked by antagonists of TRPV1, a nonselective cation channel stimulated by capsaicin [30,31]. They also demonstrated that TRPV1 activation in sensory neurons by histamine is mediated by the synthesis of 12-HPETE – a metabolite of 12-lipoxygenase and an endogenous TRPV1 activator [30,32]. Moreover, histamine-induced scratching is greatly reduced when inhibitors or blockers of H1R, PLA2, 12-lipoxygenase, or TRPV1 have been pre-treated. More importantly, histamine-induced scratching is significantly lower in TRPV1-deficient mice [30]. In line with this, the direct intradermal injection of 12-HPETE (an endogenous TRPV1 activator) was found to evoke scratching behaviors in mice [33]. However, this 12-HPETE/TRPV1 linkage is somewhat controversial, since 12-HPETE-induced scratching in mice is not blocked by the TRPV1 antagonist capsazepine [34]. However, 12-HPETE-induced scratching is reduced by topical application of capsaicin [33], which is also known to cause desensitization of TRPV1. More studies are required to determine whether 12-HPETE/TRPV1 activation mechanisms participate in H1R-related itch pathways.

It is well-known that H2R is involved in gastric acid secretion, wherein the coupling of H2R and Gaαi/o leads to cAMP production [26]. However, as mentioned above, the role of H2R in itch appears minor. H3R, on the other hand, is linked to Gaαi/o, and the activation of H3R mainly inhibits cAMP formation [35], but various down-stream signals are also generated, such as, the activations of mitogen-activated protein kinase (MAPK), PLA2, and others (For a detailed review, see [36]). However, it should be noted that H3R is predominantly expressed in the central nervous system, and was first identified in brain [37]. Although its existence in perivascular nerve terminals has been suggested [38], it appears that H3R is not present in the peripheral nervous system – at least in mice [23]. Therefore, the role of H3R in the mediation of histamine-induced itch seems minor. However, interestingly, H3R is regarded as a novel target for the treatment of obesity and cognitive disorders [39,40].

The importance of H4R in terms of itch is becoming more evident [41,42]. It is well known that the activation of H4R increases intracellular Ca2+ levels; possibly in a phospholipase C-dependent manner in mast cells [43]. Moreover, the existence of H4R in sensory neurons is suggested by the observation that an intradermally administered H4R-specific agonist elicited scratching in mice, which
were completely inhibited by pretreatment of H4R antagonist, JNJ7777120 [25]. Thus, it seems likely that the activation of H4R results in the excitation of itch-mediating histamine-sensitive afferents by increasing intracellular Ca^{2+} levels, as mentioned above for the H1R pathway.

Neurophysiology of itch fibers

Most C fibers are polymodal nociceptors that respond to noxious mechanical and heat stimuli (CMH units). These CMH units are mainly related to nociception, but are largely insensitive to or only weakly activated by histamine [44]. In addition, histamine-sensitive C-fibers do not respond to mechanical stimulation, which indicates that these itch-mediating fibers differ from polymodal C-fibers [45]. Indeed, these itch-mediating C fibers only comprise about five percent of afferent C-fibers in human cutaneous nerves [5]. Histamine activates a subset of C-fibers that innervate the superficial layer of skin and transmit electrical signals to the superficial layer of the dorsal horn of the spinal cord [5]. These signals then ascend to the thalamus through contralateral spinothalamic tracts and are eventually conducted to the somatosensory and cingulate cortex [46]. Interestingly, it was found that gastrin-releasing peptide plays a key role in mediating itch sensation, rather than pain, by interacting with gastrin-releasing peptide receptor (GRPR) at the spinal level [47]. Furthermore, the induction of scratching behavior in response to pruritogenic stimuli was significantly diminished in GRPR knockout mice, but pain-related behavioral responses to noxious stimuli were normal [47]. In addition, direct spinal injection of a GRPR antagonist considered itch-mediating behaviors [47]. Again, these results provide support for the presence of a distinct itch-mediating pathway. On the other hand, the itch elicited by cowhage (a non-histaminergic pruritogen) appears to be mediated through other distinct primary afferents [48] and through cowhage-specific non-histaminergic spinothalamic tracts [49]. Therefore, it seems that different types of itch-mediating neurons coexist in the periphery. Recently, the active compound in cowhage was identified as a novel cysteine protease "mucunain", which is a ligand for protease-activated receptor-2 and 4 [50]. Nakano et al recently similarly concluded that different types of dorsal horn neurons are associated with histamine-induced and protease-activated receptor-2-mediated itch [51]. Thus, it seems that there exist dedicated itch-mediating neuronal pathways. Moreover, the recent identification of the coexistence of histamine-sensitive and insensitive (or pruritogenic-related) pathways may provide some insight into the mechanism of itch.

Painful stimuli inhibits itch sensation

We all share the experience that scratching relieves itching. Furthermore, itch is also relieved when noxious heat is administered [52]. In other words, itch can be suppressed by painful mechanical and thermal stimuli. As stated above, itch- and pain-inducing stimuli activate distinct populations of sensory fibers, and thus, it is likely that painful stimuli modulate itch sensations centrally and not at the peripheral level. Histamine was found not to induce itch when a noxious thermal stimulus was administered within 10 cm, or to reduce itch severity if a noxious stimulus was administered more than 10 cm away [53]. Noxious cold also reduces pruritus when administered to fingertips contralateral to a pruritic stimulus [54]. Moreover, various other painful stimuli, such as, noxious heat or scratching, are known to inhibit histamine-induced itch via central mechanisms [55-57].

In fact, capsaicin, the active ingredient of hot pepper, is used as an anti-pruritic agent [58]. Capsaicin activates the nonselective cation channel TRPV1, which is regarded to induce nociception [31]. Thus, it is assumed that the anti-pruritic effect of capsaicin is attributable to its algesic effect. However, it should be noted that TRPV1 is expressed in some histamine-sensitive itch-mediating fibers as well as nociceptive C-fibers [30], which raises the question: What types of processes are involved in the sensation experienced when capsaicin is applied to the skin? In most cases, pain is likely to be the predominant perception, since approximately 80% of the primary afferent C-fibers are polymodal nociceptors [59-61]. In fact, the clinical limitation of topical capsaicin administered as an anti-pruritic agent is that it produces unbearable, burning pain [58]. Furthermore, even if capsaicin excites TRPV1 in itch fibers, the itch sensation may not dominate since itch-mediating fibers comprise only small proportion of C fibers [5]. Thus, although capsaicin may activate both pain and itch through TRPV1 receptors in their respective neurons, it is highly likely that capsaicin preferentially activates nociceptive fibers.

However, it should also be noted that repeated and prolonged applications of topical capsaicin are required to effectively reduce itch [62,63]. This method of application is believed to fully desensitize and deplete neuropeptides, such as, substance P in sensory afferents, and to thus delay the interconnection between skin and sensory neurons [58]. Indeed, it has been shown that repetitive application of topical capsaicin prevents histamine-induced itch under experimental conditions [64]. In this regard, it can also be considered that the anti-pruritic effect of capsaicin may stem from peripheral desensitization of sensory neurons and central mechanisms.

Itch can also be suppressed by cold stimuli [65-67], and in particular the anti-pruritic effect of menthol is interesting [65], because menthol activates cold receptor TRPM8 [68,69]. However, although TRPM8 is a wonderful molecular target, the mechanism whereby cold and menthol...
mitigates itch has yet to be determined. TRPA1, which is activated by noxious cold (<17°C), is also a viable target [70], but no concrete relationship between itch and TRPA1 has been established. On the other hand, warming appears to aggravate itch. Indeed, histamine-induced response is potentiated by warming [67], but no clear explanation has been offered as to how these thermal stimuli interact with itch at the molecular level. It is noteworthy that some TRP channels, like TRPV3 [71,72] respond to warming, which suggests that they participate in itch induction. However, no studies to date have focused specifically on this topic.

Unfortunately, the relationships between itch and exogeneous stimuli in disease states appear anything but straightforward. For instance, the itch-inhibitory effects of repetitive scratching and noxious heat are ineffective in patients with atopic dermatitis [73]. Similarly, the inhibitory effect of topical capsaicin on histamine-induced itch was found to be ineffective in atopic dermatitis patients, but effective in healthy controls [64], indicating that other factors are involved in disease states. Moreover, in contrast to our general understanding that cooling alleviates itch, short-term low-intensity cooling increases the intensity of histamine-induced itch above the scratch threshold in man [74,75].

Interestingly, as a corollary to the suppression of itch by painful stimuli, the reduction of pain by opioids may induce itch [76]. Patients spinaly administered μ-opioid agonists frequently experience itch [77,78], whereas μ-opioid antagonists often suppress experimentally-agonists frequently experience itch [77,78], whereas μ-opioid antagonists often suppress experimentally-induced itch [8,79]. However, not all opioids evoke itch, for example, nalbuphine (a κ-opioid agonist) has been shown to reduce μ-opioid-induced pruritus [80], and κ-opioid antagonists enhance itch, which contrasts the effects of μ-opioids [81]. Currently, it is unclear why different opioids have different effects on itch. Nevertheless, it seems evident that itch can be enhanced when pain is suppressed, and suppressed when pain is enhanced, which demonstrates the existence of an intimate physiologic interaction between underlying causes of itch and pain sensations.

**Conclusion**

Itch is probably viewed as trivial malady by most, but to many patients itch is a distressing condition. Although it has been revealed by many researchers that there is a histamine-independent itch, this should not detract from the fact that histamine is deeply involved in various itch sensations. Recent advances in molecular biology have helped reveal the key molecular players involved, but a considerable amount of effort will be required to determine how histamine-induced itch is mediated and can be inhibited. In our opinion, a thorough understanding of the pruriogenic actions of histamine is required if we are to resolved itch symptoms at the clinical level.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

WS drafted the manuscript and UO revised the manuscript.

**Acknowledgments**

This work was supported by the Swedish Research Council (grants K 2006-02076 and K 2007-02067), and the Stockholm County Council (grants 06-0250-12 and 07-0215-22). The authors are very grateful for the support.

**References**

1. Hashiro M, Okamura M: Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. J Dermatol Sci 1997, 14(3):63-67.
2. Sheehan-Dare RA, Henderson MJ, Cotterill JA: Anxiety and depression in patients with chronic urticaria and generalized pruritus. Br J Dermatol 1990, 123:769-774.
3. Paus R, Schmelz M, Biró T, Steinhoff M: Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006, 116:1174-1186.
4. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M: The neurobiology of itch. Nat Rev Neurosci 2006, 7:533-547.
5. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE: Specific C-receptors for itch in human skin. J Neurosci 1997, 17:8003-8008.
6. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjörk HE, Handwerker HO: Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003, 89:2441-2448.
7. Magerl W, Westerman RA, Mohner B, Handwerker HO: Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. J Invest Dermatol 1990, 94:347-352.
8. Heyer G, Dotzer M, Diepgen TL, Handwerker HO: Opiate and H1 antagonist effects on histamine induced pruritus and allognosis. Pain 1997, 73:239-243.
9. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M: Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol Res 2003, 139:1455-1458.
10. Kaufman DW, Kelly JP, Rosenburg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Sone survey. JAMA 2002, 287:337-344.
11. Bendict EP, Bader S, Lam KB: Studies of the mechanism of acute vascular reactions to injury. I. The relationship of mast cells and histamine to the production of edema by ovomucoid in rats. Acta Arch Pathol 1955, 60:104-115.
12. Rowley DA, Bendict EP: 5-Hydroxytryptamine and histamine as mediators of the vascular injury produced by agents which damage mast cells in rats. J Exp Med 1956, 103:399-412.
13. Tani E, Shiosaka S, Sato M, Ishikawa T, Tohyama M: Histamine acts directly on calcitonin gene-related peptide- and substance P-containing trigeminal ganglion neurons as assessed by calcium influx and immunocytochemistry. Neurosci Lett 1990, 115:171-176.
14. Simons FE, Simons KJ, Becker AB, Haydey RP: Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. J Pediatr 1984, 104:123-127.
15. Krause L, Shuster S: Mode of action of H1 antihistamines in itch. Br J Dermatol 1983, 109:30-30.
16. Katagiri K, Arakawa S, Hatanaka Y, Fujikawa S: Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. J Dermatol 2006, 33:75-79.
17. Hagermark O, Strandberg K, Gronneberg R: Effects of histamine receptor antagonists on histamine-induced responses in human skin. Acta Derm Venereol 1979, 59:297-300.
18. Davies MG, Greaves MW: Sensory responses of human skin to synthetic histamine analogues and histamine. Br J Clin Pharmaocol 1980, 9:461-465.
19. Bell JK, McQueen DS, Rees JL: Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in B10 C mice. Br J Pharmacol 2004, 142:374-380.
20. Summey BT Jr, Yosipovitch G: Pharmacological advances in the systemic treatment of itch. Dermatol Ther 2005, 18:328-332.
21. Sugimoto Y, Iba Y, Nakamura Y, Kayasuga R, Kamei C: Pruritus-associated response mediated by cutaneous histamine H3 receptors. Curr Opin Allergy Clin Immunol 2004, 4:456-459.
22. Hossen MA, Sugimoto Y, Kayasuga R, Kamei C: Involvement of histamine H3 receptors in scratching behaviour in mast cell-deficient mice. Br J Dermatol 2003, 149:17-22.
23. Hossen MA, Inoue T, Shinmei Y, Fujita Y, Watanabe T, Kamei C: Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice. J Pharmacol Sci 2006, 100:297-302.
24. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2007, 282:20390-20396.
25. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen DL, Thurmond RL: Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007, 119:176-183.
26. Bakera RA, Timmerman HJ, Lee CH: Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 2002, 17:27-64.
27. Nicolson TA, Bevan S, Richards CD: Characterisation of the calcium responses to histamine in capsaicin-sensitive and capsaicin-insensitive sensory neurones. 0306-4522 2002, 110:329-338.
28. Han SK, Mancino V, Simon MI: Phospholipase Cbeta 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurones. 0896-6723 2006, 328:2891-2896.
29. Kim BM, Lee SH, Shim WS, Oh U: Histamine-induced Ca(2+) influx via the PLA(2)/lipoxgenase/TRPV1 pathway in rat sensory neurones. Neurosci Lett 2004, 361:159-162.
30. Shim WS, Park MH, Lee HH, Kim M, Kim M, Koo JY, Lee CH, Kim M, Oh U: TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxigenase. J Neurosci 2007, 27:2331-2337.
31. Caterina Mj, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. 0028-036X 1997, 389:816-824.
32. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U: Direct activation of capsaicin receptors by products of lipoxigenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000, 97:1651-1656.
33. Kim DK, Kim Hj, Sung KS, Kim H, Cho SA, Kim KM, Lee CH, Kim Jl: 12(S)-HPETE induces itch-associated scratchings in mice. Eur J Pharmacol 2005, 54:30-33.
34. Kim DK, Kim Hj, Kim H, Koh JY, Kim KM, Noh MS, Kim Jl, Lee CH: Involvement of serotonin receptors S-HT1 and S-HT2 in 12(S)-HPETE-induced scratching in mice. Eur J Pharmacol 2008, 579:390-394.
35. Leurs R, Bakera RA, Timmerman H, de Esch Jl: The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005, 4:107-120.
36. Borgers G, Bakker RA, Leurs R: Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 2007, 73:1195-1204.
37. Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptors. 0028-036X 1983, 107:832-837.
38. Ishikawa S, Sperelakis N: A novel class (H3) of histamine receptors on perivascular nerve terminals. 0028-0836 1987, 327:158-160.
39. Esbenshade TA, Fox GB, Coward MD: Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interact 2006, 6:77-88.
40. Esbenshade TA, Browman KE, Bittner RS, Strakova M, Coward MD, Brioni JD: The histamine H(3) receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008, 154:606-617.
41. Huang JF, Thurmond RL: The new biology of histamine receptors. Curr Allergy Asthma Rep 2008, 8:21-27.
42. Thurmond RL, Gelfand EVW, Dunford PJ: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
43. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP: Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2001, 305:121-127.
44. Handwerker HO, Forster C, Kirschhofer C: Discharge patterns of human C-fibers induced by itching and burning stimuli. J Neurophysiol 1991, 66:307-315.
45. Schmelz M, Schmid R, Handwerker HO, Torebjork HE: Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. 0006-8950 2000, 123(Pt 3):560-571.
46. Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001, 4:72-77.
47. Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. 0028-0836 2007, 448:700-703.
48. Johaneke LM, Meyer RA, Hartke T, Hobelmann JG, Maire DN, Lamotte RH, Ringkamp M: Psychophysical and psychophysical evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007, 27:7490-7497.
49. Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr: The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007, 27:10007-10014.
50. Reddy VB, Iuga AO, Shimada SG, Lamotte RH, Lerner EA: Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 2008, 28:4331-4335.
51. Nakano T, Ando T, Lee JB, Kuraishi Y: Different dorsal horn neurones responding to histamine and allergic itch stimuli. 0959-4963 2008, 19:723-726.
52. Schmelz M: Itch – mediators and mechanisms. J Dermatol Sci 2007, 41:57-64.
53. Bickford RG: Experiments relating to the itch sensation, its peripheral mechanism, and central pathways. Clin Sci 1937, 3:377-386.
54. Murray FS, Weaver MM: Effects of ipsilateral and contralateral counterirritation on experimentally produced itch in human beings. J Comp Physiol Psychol 1975, 89:819-826.
55. Fruhstorfer H, Hermanns M, Latzke L: The effects of thermal stimulation on clinical and experimental itch. Pain 1986, 24:259-269.
56. Ward L, Wright E, McMahon SB: A comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain 1996, 64:129-138.
57. Yosipovitch G, Duque ML, Fast K, Dawn AG, Coghill RC: Scratching and noxious heat stimuli inhibit itch in humans: a psychological study. Br J Dermatol 2007, 156(629):634.
58. Biro T, Toth BI, Marinsca R, Dobrosi N, Gezcy T, Paus R: TRP channels as novel players in the pathogenesis and therapy of itch. Biochem Pharmacol 2007, 77:1004-1021.
59. Esbenshade TA, Fox GB, Coward MD: Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interact 2006, 6:77-88.
60. Esbenshade TA, Browman KE, Bittner RS, Strakova M, Coward MD, Brioni JD: The histamine H(3) receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008, 154:606-617.
61. Huang JF, Thurmond RL: The new biology of histamine receptors. Curr Allergy Asthma Rep 2008, 8:21-27.
62. Thurmond RL, Gelfand EVW, Dunford PJ: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
67. Mizumura K, Koda H: Potentiation and suppression of the histamine response by raising and lowering the temperature in canine visceral polymodal receptors in vitro. Neurosci Lett 1999, 266:9-12.

68. McKemy DD, Neuhausser WM, Julius D: Identification of a cold receptor reveals a general role for TRP channels in thermosensation. 0028-0836 2002, 416:52-58.

69. Peier AM, Mogrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, Patapoutian A: A TRP channel that senses cold stimuli and menthol. 0092-8674 2002, 108:705-715.

70. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A: ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. 0092-8674 2003, 112:819-829.

71. Smith GD, Gunthorpe MJ, Kelsell DE, Hayes PD, Reilly P, Facer P, Wright JE, Jerman JC, Walhin JP, Ooi L, Egerton J, Charles KJ, Smart D, Randall AD, Anand P, Davis JB: TRPV3 is a temperature-sensitive vanilloid receptor-like protein. 0028-0836 2002, 418:186-190.

72. Xu H, Ramsey IS, Kotecha SA, Moran MM, Chong JA, Lawson D, Ge P, Lily J, Silos-Santiago I, Xie Y, DiStefano PS, Curtis R, Clapham DE: TRPV3 is a calcium-permeable temperature-sensitive cation channel. 0028-0836 2002, 418:181-186.

73. Ishii Y, Coghill RC, Patel TS, Dawn A, Fountain J, Oshiro Y, Yosipovitch G: Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis. Br J Dermatol 2008, 158:78-83.

74. Pfab F, Valet M, Sprenger T, Toelle TR, Athanasiadis GI, Behrendt H, Ring J, Darsow U: Short-term alternating temperature enhances histamine-induced itch: a biphasic stimulus model. J Invest Dermatol 2006, 126:2673-2678.

75. Valet M, Pfab F, Sprenger T, Woller A, Zimmer C, Behrendt H, Ring J, Darsow U, Tolle TR: Cerebral processing of histamine-induced itch using short-term alternating temperature modulation – an FMRI study. J Invest Dermatol 2008, 128:426-433.

76. Akanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH: Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anaesthesia. Somatosens Mot Res 1999, 16:291-298.

77. Chaney MA: Side effects of intrathecal and epidural opioids. Can J Anaesth 1995, 42:891-903.

78. Kaj PH, Tan KH: Pruritus – itching for a cause and relief 0003-2409 1996, 51:1133-1138.

79. Ko MC, Song MS, Edwards T, Lee H, Naughton NN: The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004, 310:169-176.

80. Kjellberg F, Tramer MR: Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001, 18:346-357.

81. Kamei J, Nagase H: Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001, 418:141-145.